Compare IIIV & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIV | DAWN |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.1M | 2.2B |
| IPO Year | 2018 | 2021 |
| Metric | IIIV | DAWN |
|---|---|---|
| Price | $23.77 | $21.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $33.20 | $27.61 |
| AVG Volume (30 Days) | 392.0K | ★ 5.0M |
| Earning Date | 05-06-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $9.05 | $53.52 |
| Revenue Next Year | $8.07 | $27.10 |
| P/E Ratio | $1,176.50 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $19.89 | $5.64 |
| 52 Week High | $33.97 | $21.23 |
| Indicator | IIIV | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 82.81 |
| Support Level | $22.51 | $6.40 |
| Resistance Level | $27.02 | N/A |
| Average True Range (ATR) | 0.81 | 0.71 |
| MACD | 0.32 | 0.99 |
| Stochastic Oscillator | 87.65 | 99.96 |
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.